Caribou Biosciences prices upsized $125M public offering at $6.50/sh

Caribou Biosciences, Inc.

Priced 19,230,769 shares at $6.50 per share; underwriters granted 30-day option for 2,884,615 additional shares.
Gross proceeds ~$125M; net proceeds to Caribou expected ~$116.9M after discounts and expenses.
Offering expected to close on or about July 18, 2023; BofA, Leerink, Evercore, RBC as book-runners.
All shares sold by Caribou; proceeds for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Caribou Biosciences, Inc. entered into Underwriting Agreement with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters (effective 2023-07-13).

Action: entry
Agreement: underwriting
Counterparty: BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters
Effective: 2023-07-13

Exact text from the filing

On July 13, 2023, Caribou Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 19,230,769 shares of its common stock

View on SEC.gov

Browse all material agreements →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.